Revolution Medicines, Inc. RVMD
At closeNov 4, 2026, 7:47 PM EST
After hours · Nov 4, 7:47 PM ET
- YTD
- +150.72%
- 1 year
- +240.96%
- Market cap
- 42.80B
- EPS (ttm)
- -8.87
- Shares out
- 214.34M
- Forward P/E
- -34.65
- YTD return
- +150.72%
- 1-year return
- +240.96%
- Volume
- 2.55M
- Avg volume
- 1.92M
- Open
- 198.50
- Previous close
- 194.23
- Day's range
- 192.34 – 201.79
- 52-week range
- 58.00 – 224.31
- Beta
- 1.43
- Analysts
- Strong Buy
- Price target
- 258.84 (+29.6%)
- Earnings date
- Nov 4, 2026
5m +11.04 (+5.85%)
Key statistics
- Enterprise value
- 38.88B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 16.42
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -711.61M
- Total cash
- 3.94B
- Total debt
- 1.19B
- Return on equity
- -79.09%
- Short % of float
- 6.37%
- 50-day average
- 198.45
- 200-day average
- 156.73
Analyst view
Consensus: strong buy
- Target (low)
- 179.00
- Target (mean)
- 258.84
- Target (high)
- 320.00
- Strong buy5
- Buy19
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -2.38.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -2.35 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -2.04 | -3.06 | -1.02 | -50.00% |
| May 6, 2026 | Mar 31, 2026 | -1.84 | -2.29 | -0.45 | -24.46% |
| Feb 25, 2026 | Dec 31, 2025 | -1.58 | -1.86 | -0.28 | -17.72% |
| Nov 5, 2025 | Sep 30, 2025 | -1.42 | -1.61 | -0.19 | -13.38% |
| Aug 6, 2025 | Jun 30, 2025 | -1.14 | -1.31 | -0.17 | -15.11% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | TD Cowen | reit | Buy | Buy |
| Oct 19, 2026 | Truist Securities | main | Buy | Buy |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Oct 15, 2026 | Needham | reit | Buy | Buy |
| Oct 14, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 8, 2026 | RBC Capital | main | Outperform | Outperform |
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- revmed.com
News
Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Beats Revenue Estimates 
Revolution Medicines Q3 2026 Earnings Call Transcript 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
Revolution Medicines Q3 EPS $(1.90) Beats $(2.42) Estimate, Sales $197.559M May Not Be Comparable To $23.495M Estimate 
Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress 
ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test 
Earnings Volatility Watch: 10 Stocks Are Set to Swing More Than 10% This Week 
Could Revolution Medicines Be a Millionaire-Maker Stock? 
Jim Cramer: This Tech Stock ‘Sells At A Low Multiple’ 
Revolution Medicines, Inc. $RVMD Holdings Cut by Citizens Financial Group Inc. RI
Your note
Sign in to keep a note on RVMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERS JACK LEE | Chief Financial Officer | Sale | Jun 23, 2026 | 123,269 |
| BORISY ALEXIS | Director | Stock Award(Grant) | Jun 17, 2026 | 2,340,080 |
| GOLDSMITH MARK A | Chief Executive Officer | Sale | Aug 20, 2026 | 0 |
| HORN MARGARET A | Chief Operating Officer | Sale | Jun 16, 2026 | 154,647 |
| HORNING SANDRA | Director | Stock Award(Grant) | Jun 17, 2026 | 97,765 |
| KELSEY STEPHEN MICHAEL | Officer | Sale | Sep 10, 2026 | 291,876 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 6.39% | 13,695,790 | 2.74B | Jun 29, 2026 |
| Farallon Capital Management LLC | 6.32% | 13,550,796 | 2.71B | Jun 29, 2026 |
| FMR, LLC | 5.69% | 12,200,422 | 2.44B | Jun 29, 2026 |
| Baker Bros. Advisors, LP | 5.34% | 11,443,357 | 2.29B | Jun 29, 2026 |
| Jupiter Topco LLC | 5.01% | 10,736,145 | 2.14B | Jun 29, 2026 |
| Darwin Global Management, Ltd. | 4.96% | 10,629,822 | 2.12B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.99% | 6,412,413 | 1.28B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.16% | 4,631,150 | 924.84M | Jun 29, 2026 |
| Growth Fund of America | 1.38% | 2,964,768 | 592.06M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.25% | 2,670,853 | 533.37M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.15% | 2,472,885 | 493.84M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.07% | 2,291,511 | 457.61M | Jun 29, 2026 |